DEVELOPMENT AND REGISTRATION OF A COMBINED DRUG FOR THE TREATMENT OF HIV INFECTION ON THE BASIS OF ON NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS (NRTI) PHOSPHAZIDE AND LAMIVUDINE
The article discusses the development process of a combined medicinal product Phosphaladin® intended for the treatment of HIV infection, based on phosphazide and lamivudine. A brief review of epidemiological situation on HIV infection taking into account the import substitution policy in the pharmac...
Saved in:
Main Authors: | A. F. Khohlov, B. V. Brovchenko, A. A. Smirnov |
---|---|
Format: | Article |
Language: | Russian |
Published: |
LLC Center of Pharmaceutical Analytics (LLC «CPHA»)
2019-01-01
|
Series: | Разработка и регистрация лекарственных средств |
Subjects: | |
Online Access: | https://www.pharmjournal.ru/jour/article/view/221 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Сасо-2 INTESTINAL PERMEABILITY AND Pgp-AFFINITY OF PHOSPHAZIDE
by: D. Yu. Grebenkin, et al.
Published: (2019-01-01) -
EVALUATION OF THE EFFICACY AND SAFETY OF THE ART REGIMENS CONTAINING LOW DOSES PHOSPHAZID
by: N. V. Sizova, et al.
Published: (2017-10-01) -
DISSOLUTION PROFILE STUDY FOR INNOVATION ANTI-RETROVIRAL DRUG PRODUCT NIKAVIR® AND ITS FIXED COMBINATION WITH LAMIVUDINE (PHOSPHALADINE®)
by: I. E. Shohin, et al.
Published: (2019-01-01) -
Lipidic strategy for improving bioavailability of nucleoside HIV reverse transcriptase inhibitor
by: N. S. Shastina, et al.
Published: (2011-04-01) -
Efficacy and safety of novel russian non-nucleoside reverse transcriptase inhibitor elsulfavirine in combination with 2 nucleoside/nucleotide reverse transcriptase inhibitors in first-line HIV treatment – 96-week study
by: A. V. Kravchenko, et al.
Published: (2018-07-01)